Global Capecitabine Sales 麻豆原创 Report, Competitive Analysis and Regional Opportunities 2025-2031

Publication ID:

PB504262365

Publication Date:

April 25, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 4,250.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global Capecitabine market size was US$ 1018 million in 2024 and is forecast to a readjusted size of US$ 990 million by 2031 with a CAGR of -0.4% during the forecast period 2025-2031.
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, which is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Common side effects include abdominal pain, vomiting, diarrhea, weakness, and rashes. Other severe side effects include blood clotting problems, allergic reactions, heart problems, and low blood cell counts. It is not recommended in people with kidney problems. Use during pregnancy may result in harm to the baby. Capecitabine, inside the body, is converted to 5-fluorouracil (5-FU) through which it acts. It belongs to the class of medications known as fluoropyrimidines, which also includes 5-fluorouracil and tegafur.
Roche, Teva and Mylan are the top 3 of Capecitabine, with about 87% market shares.
The global Capecitabine market is strategically segmented by company, region (country), by Type, and by Application. This report empowers stakeholders to capitalize on emerging opportunities, optimize product strategies, and outperform competitors through data-driven insights on sales, revenue, and forecasts across regions, by Type, and by Application for 2020-2031.
麻豆原创 Segmentation
By Company:
Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero
By Type: (Dominant Segment vs High-Margin Innovation)
500 mg
150 mg
By Application: (Core Demand Driver vs Emerging Opportunity)
Breast Cancer
Colorectal Cancer
Stomach Cancer
By Region
Macro-Regional Analysis: 麻豆原创 Size & Growth Forecasts
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Micro-Local 麻豆原创 Deep Dive: Strategic Insights
- Competitive Landscape: Player dominance vs. disruptors (e.g., Roche in Europe)
- Emerging Product Trends: 500 mg adoption vs. 150 mg premiumization
- Demand-Side Dynamics: Breast Cancer growth in China vs. Colorectal Cancer potential in North America
- Localized Consumer Needs: Regulatory hurdles in EU vs. price sensitivity in India
Focus 麻豆原创s:
North America
Europe
Middle East & Africa
Japan
China
India
Chapter Outline
Chapter 1: Report scope, executive summary, and market evolution scenarios (short/mid/long term).
Chapter 2: Quantitative analysis of Capecitabine market size and growth potential at global, regional, and country levels.
Chapter 3: Competitive benchmarking of manufacturers (revenue, market share, M&A, R&D focus).
Chapter 4: Type-based segmentation analysis 鈥� Uncovering blue ocean markets (e.g., 150 mg in China).
Chapter 5: Application-based segmentation analysis 鈥� High-growth downstream opportunities (e.g., Colorectal Cancer in India).
Chapter 6: Regional sales and revenue breakdown by company, type, application and customer.
Chapter 7: Key manufacturer profiles 鈥� Financials, product portfolios, and strategic developments.
Chapter 8: 麻豆原创 dynamics 鈥� Drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 9: Actionable conclusions and strategic recommendations.
Why This Report?
This is not just another market study. By fusing global trend analysis with hyper-local operational intelligence, we deliver:
- Risk-Controlled 麻豆原创 Entry: Navigate regulatory complexities in focus markets (e.g., China鈥檚 policies).
- Product Portfolio Optimization: Align offerings with regional preferences (e.g., 500 mg dominance in Europe vs. 150 mg demand in MEA).
- Competitor Counterstrategies: Decode player tactics in fragmented vs. consolidated markets.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 Capecitabine Product Scope
1.2 Capecitabine by Type
1.2.1 Global Capecitabine Sales by Type (2020 & 2024 & 2031)
1.2.2 500 mg
1.2.3 150 mg
1.3 Capecitabine by Application
1.3.1 Global Capecitabine Sales Comparison by Application (2020 & 2024 & 2031)
1.3.2 Breast Cancer
1.3.3 Colorectal Cancer
1.3.4 Stomach Cancer
1.4 Global Capecitabine 麻豆原创 Estimates and Forecasts (2020-2031)
1.4.1 Global Capecitabine 麻豆原创 Size in Value Growth Rate (2020-2031)
1.4.2 Global Capecitabine 麻豆原创 Size in Volume Growth Rate (2020-2031)
1.4.3 Global Capecitabine Price Trends (2020-2031)
1.5 Assumptions and Limitations
2 麻豆原创 Size and Prospective by Region
2.1 Global Capecitabine 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2 Global Capecitabine Retrospective 麻豆原创 Scenario by Region (2020-2025)
2.2.1 Global Capecitabine Sales 麻豆原创 Share by Region (2020-2025)
2.2.2 Global Capecitabine Revenue 麻豆原创 Share by Region (2020-2025)
2.3 Global Capecitabine 麻豆原创 Estimates and Forecasts by Region (2026-2031)
2.3.1 Global Capecitabine Sales Estimates and Forecasts by Region (2026-2031)
2.3.2 Global Capecitabine Revenue Forecast by Region (2026-2031)
2.4 Major Region and Emerging 麻豆原创 Analysis
2.4.1 North America Capecitabine 麻豆原创 Size and Prospective (2020-2031)
2.4.2 Europe Capecitabine 麻豆原创 Size and Prospective (2020-2031)
2.4.3 Middle East & Africa Capecitabine 麻豆原创 Size and Prospective (2020-2031)
2.4.4 Japan Capecitabine 麻豆原创 Size and Prospective (2020-2031)
2.4.5 China Capecitabine 麻豆原创 Size and Prospective (2020-2031)
2.4.6 India Capecitabine 麻豆原创 Size and Prospective (2020-2031)
3 Global 麻豆原创 Size by Type
3.1 Global Capecitabine Historic 麻豆原创 Review by Type (2020-2025)
3.1.1 Global Capecitabine Sales by Type (2020-2025)
3.1.2 Global Capecitabine Revenue by Type (2020-2025)
3.1.3 Global Capecitabine Price by Type (2020-2025)
3.2 Global Capecitabine 麻豆原创 Estimates and Forecasts by Type (2026-2031)
3.2.1 Global Capecitabine Sales Forecast by Type (2026-2031)
3.2.2 Global Capecitabine Revenue Forecast by Type (2026-2031)
3.2.3 Global Capecitabine Price Forecast by Type (2026-2031)
3.3 Different Types Capecitabine Representative Players
4 Global 麻豆原创 Size by Application
4.1 Global Capecitabine Historic 麻豆原创 Review by Application (2020-2025)
4.1.1 Global Capecitabine Sales by Application (2020-2025)
4.1.2 Global Capecitabine Revenue by Application (2020-2025)
4.1.3 Global Capecitabine Price by Application (2020-2025)
4.2 Global Capecitabine 麻豆原创 Estimates and Forecasts by Application (2026-2031)
4.2.1 Global Capecitabine Sales Forecast by Application (2026-2031)
4.2.2 Global Capecitabine Revenue Forecast by Application (2026-2031)
4.2.3 Global Capecitabine Price Forecast by Application (2026-2031)
4.3 New Sources of Growth in Capecitabine Application
5 Competition Landscape by Players
5.1 Global Capecitabine Sales by Players (2020-2025)
5.2 Global Top Capecitabine Players by Revenue (2020-2025)
5.3 Global Capecitabine 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Capecitabine as of 2024)
5.4 Global Capecitabine Average Price by Company (2020-2025)
5.5 Global Key Manufacturers of Capecitabine, Manufacturing Sites & Headquarters
5.6 Global Key Manufacturers of Capecitabine, Product Type & Application
5.7 Global Key Manufacturers of Capecitabine, Date of Enter into This Industry
5.8 Manufacturers Mergers & Acquisitions, Expansion Plans
6 Region Analysis
6.1 North America 麻豆原创: Players, Segments, Downstream and Major Customers
6.1.1 North America Capecitabine Sales by Company
6.1.1.1 North America Capecitabine Sales by Company (2020-2025)
6.1.1.2 North America Capecitabine Revenue by Company (2020-2025)
6.1.2 North America Capecitabine Sales Breakdown by Type (2020-2025)
6.1.3 North America Capecitabine Sales Breakdown by Application (2020-2025)
6.1.4 North America Capecitabine Major Customer
6.1.5 North America 麻豆原创 Trend and Opportunities
6.2 Europe 麻豆原创: Players, Segments, Downstream and Major Customers
6.2.1 Europe Capecitabine Sales by Company
6.2.1.1 Europe Capecitabine Sales by Company (2020-2025)
6.2.1.2 Europe Capecitabine Revenue by Company (2020-2025)
6.2.2 Europe Capecitabine Sales Breakdown by Type (2020-2025)
6.2.3 Europe Capecitabine Sales Breakdown by Application (2020-2025)
6.2.4 Europe Capecitabine Major Customer
6.2.5 Europe 麻豆原创 Trend and Opportunities
6.3 Middle East & Africa 麻豆原创: Players, Segments, Downstream and Major Customers
6.3.1 Middle East & Africa Capecitabine Sales by Company
6.3.1.1 Middle East & Africa Capecitabine Sales by Company (2020-2025)
6.3.1.2 Middle East & Africa Capecitabine Revenue by Company (2020-2025)
6.3.2 Middle East & Africa Capecitabine Sales Breakdown by Type (2020-2025)
6.3.3 Middle East & Africa Capecitabine Sales Breakdown by Application (2020-2025)
6.3.4 Middle East & Africa Capecitabine Major Customer
6.3.5 Middle East & Africa 麻豆原创 Trend and Opportunities
6.4 Japan 麻豆原创: Players, Segments, Downstream and Major Customers
6.4.1 Japan Capecitabine Sales by Company
6.4.1.1 Japan Capecitabine Sales by Company (2020-2025)
6.4.1.2 Japan Capecitabine Revenue by Company (2020-2025)
6.4.2 Japan Capecitabine Sales Breakdown by Type (2020-2025)
6.4.3 Japan Capecitabine Sales Breakdown by Application (2020-2025)
6.4.4 Japan Capecitabine Major Customer
6.4.5 Japan 麻豆原创 Trend and Opportunities
6.5 China 麻豆原创: Players, Segments, Downstream and Major Customers
6.5.1 China Capecitabine Sales by Company
6.5.1.1 China Capecitabine Sales by Company (2020-2025)
6.5.1.2 China Capecitabine Revenue by Company (2020-2025)
6.5.2 China Capecitabine Sales Breakdown by Type (2020-2025)
6.5.3 China Capecitabine Sales Breakdown by Application (2020-2025)
6.5.4 China Capecitabine Major Customer
6.5.5 China 麻豆原创 Trend and Opportunities
6.6 India 麻豆原创: Players, Segments, Downstream and Major Customers
6.6.1 India Capecitabine Sales by Company
6.6.1.1 India Capecitabine Sales by Company (2020-2025)
6.6.1.2 India Capecitabine Revenue by Company (2020-2025)
6.6.2 India Capecitabine Sales Breakdown by Type (2020-2025)
6.6.3 India Capecitabine Sales Breakdown by Application (2020-2025)
6.6.4 India Capecitabine Major Customer
6.6.5 India 麻豆原创 Trend and Opportunities
7 Company Profiles and Key Figures
7.1 Roche
7.1.1 Roche Company Information
7.1.2 Roche Business Overview
7.1.3 Roche Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.1.4 Roche Capecitabine Products Offered
7.1.5 Roche Recent Development
7.2 Teva
7.2.1 Teva Company Information
7.2.2 Teva Business Overview
7.2.3 Teva Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.2.4 Teva Capecitabine Products Offered
7.2.5 Teva Recent Development
7.3 Mylan
7.3.1 Mylan Company Information
7.3.2 Mylan Business Overview
7.3.3 Mylan Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.3.4 Mylan Capecitabine Products Offered
7.3.5 Mylan Recent Development
7.4 Hikma
7.4.1 Hikma Company Information
7.4.2 Hikma Business Overview
7.4.3 Hikma Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.4.4 Hikma Capecitabine Products Offered
7.4.5 Hikma Recent Development
7.5 Hengrui Medicine
7.5.1 Hengrui Medicine Company Information
7.5.2 Hengrui Medicine Business Overview
7.5.3 Hengrui Medicine Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.5.4 Hengrui Medicine Capecitabine Products Offered
7.5.5 Hengrui Medicine Recent Development
7.6 Cipla
7.6.1 Cipla Company Information
7.6.2 Cipla Business Overview
7.6.3 Cipla Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.6.4 Cipla Capecitabine Products Offered
7.6.5 Cipla Recent Development
7.7 Reliance Group
7.7.1 Reliance Group Company Information
7.7.2 Reliance Group Business Overview
7.7.3 Reliance Group Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.7.4 Reliance Group Capecitabine Products Offered
7.7.5 Reliance Group Recent Development
7.8 Hetero
7.8.1 Hetero Company Information
7.8.2 Hetero Business Overview
7.8.3 Hetero Capecitabine Sales, Revenue and Gross Margin (2020-2025)
7.8.4 Hetero Capecitabine Products Offered
7.8.5 Hetero Recent Development
8 Capecitabine Manufacturing Cost Analysis
8.1 Capecitabine Key Raw Materials Analysis
8.1.1 Key Raw Materials
8.1.2 Key Suppliers of Raw Materials
8.2 Proportion of Manufacturing Cost Structure
8.3 Manufacturing Process Analysis of Capecitabine
8.4 Capecitabine Industrial Chain Analysis
9 麻豆原创ing Channel, Distributors and Customers
9.1 麻豆原创ing Channel
9.2 Capecitabine Distributors List
9.3 Capecitabine Customers
10 Capecitabine 麻豆原创 Dynamics
10.1 Capecitabine Industry Trends
10.2 Capecitabine 麻豆原创 Drivers
10.3 Capecitabine 麻豆原创 Challenges
10.4 Capecitabine 麻豆原创 Restraints
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.1.1 Research Programs/Design
12.1.1.2 麻豆原创 Size Estimation
12.1.1.3 麻豆原创 Breakdown and Data Triangulation
12.1.2 Data Source
12.1.2.1 Secondary Sources
12.1.2.2 Primary Sources
12.2 Author Details
12.3 Disclaimer

Companies Mentioned:

Roche
Teva
Mylan
Hikma
Hengrui Medicine
Cipla
Reliance Group
Hetero

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.